On July 14, 2017, BGI Genomics was officially listed and became the 2001st listed company of the Shenzhen Stock Exchange. BGI Genomics is one of the world’s leading genomics tests and research service providers, providing genomics tests and research services for medical institutions, research institutions, enterprises, and institutions through genetic testing and other means. BGI Genomics is committed to helping and accelerating scientific innovation, strengthening the prevention and control of cancer and other genetic diseases, improving diagnostic tools for the rapid diagnosis of infectious disease, and helping the development of precision medicine. Relying on cutting edge bioinformatics pipelines, advanced R&D, high-performance proprietary NGS sequencing technology, mass spectrometers, and underpinned by a decade of commercial experience, BGI Genomics provides its customers with expert and affordable clinical molecular diagnostic solutions and NGS research services.

Da An Gene Co., Ltd. of Sun Yat-sen University relying on the abundant scientific research platform of Sun Yat-sen University, it is a high-tech biomedical enterprise which is led by molecular diagnostic technology and integrates the research and development, production and sales of clinical test reagents and instruments as well as the clinical test service of national chain independent medical laboratories in China.

The company was listed on the Shenzhen Stock Exchange on August 9, 2004, becoming the first listed company among colleges and universities in Guangdong province. It now has more than 797 million shares and a market value of more than 32.9 billion.

The company’s positioning has been changed from a single product to the layout of the entire industrial chain and is committed to exploring a practical model in China’s health undertakings. The company has always been in a leading position in molecular biology technologies, especially the research, development, and application of gene diagnosis technology and reagent products, independently developed the fluorescence quantitative PCR gene diagnosis technology. It has more than a hundred registered medical device certificates, more than 50 CE certificates, and 6 CMDCAS certificates, besides 54 products were identified as high-tech products in Guangdong province, which provides a powerful guarantee for our products entering the domestic and international market. Meanwhile, the company sought for transformation, explored actively, built a value system featuring openness, sharing, cooperation, and win-win results, implemented the open mode of the all-around platform, shared the value of growth, and committed to the health care integration of upstream and downstream suppliers in the field of a strategic goal. At present, over 300 health care enterprises were invested by the company in the incubator model, which completed our layout of the whole industry chain, and we hope to make our contribution to the health industry in China.

In recent years, the company has undertaken many national projects and won awards, such as the national “863” project, “973” project, “ninth five-year plan”, “tenth five-year plan”, and “eleventh five-year plan”.

Maccura Biotechnology Co., Ltd. is a professional enterprise to research and manufacture clinical IVD products.  Founded in 1994, Maccura is a hi-tech enterprise certified by related national departments, focusing on the research, manufacture, marketing, and services of IVD products. It has passed the certification of CMD ISO13485, CQC ISO14001, TUV ISO13485, as well as the CE certification for some products. Maccura became the first Chinese enterprise member of IFCC in 2010 and been certified by CNAS in 2013. In 2015, the reference system department of Maccura had been the first enterprise laboratory in China to enter the JCTLM list and become the cooperation member of IRMM to undertake the assignment for international reference materials.

Maccura has a world-class R&D, manufacture, and operation team, have completed the layout of the whole industrial chain from biological raw materials, medical laboratory products to professional services, and have the systematic ability to research and manufacture IVD instruments, reagents, calibrators and control materials. Our products have covered platforms of biochemistry, immunoassay, POCT, hematology, molecular diagnosis, and pathology, and could meet more than 90% requirements of medical labs with the product integration.

Maccura has closely cooperated with domestic and international R&D institutions, established a special innovation system by introducing advanced devices for R&D, manufacture, and testing. Meanwhile, we have also cooperated with advanced social units, labs, and individuals to establish an innovative open lab for laboratory medicine.

With rich experience in marketing and channel management, Maccura provides distributors and end-users with perfect professional services.

Getein Biotech, Inc. is a Nanjing headquartered and globally operated in-vitro diagnostic company, specializing in analytical medical devices, point-of-care testing kits for more than 15 years. The company sits on a 10.5 square kilometers science park and is equipped with state-of-the-art R&D and production facilities. Our broad product lines consist of cardiovascular, inflammatory, diabetes, fertility, renal, liver, and specialty assays, among many others. 

Our mission to “Pursue Excellence and Deliver Health” means a commitment to keep patients’ well-being in mind. We strive to deliver high-quality, reliable, and affordable point-of-care and diagnostic solutions to professional clinical laboratories, hospitals, and physician offices. Our commitment is backed by our quality first policy, talented team, innovative technology, and accountability attitude.

Getein has over 28,000 square-feet of R&D and manufacturing facilities that follow GMP standards and a 60-acre animal breeding base that complies with government regulation. We have obtained ISO13485:2016, and products are CE Marking. Our Total Quality Control System ensures that quality touches everything we produce.

Talent-oriented Team Getein emphasizes employee talent management, both mentally and physically. We encourage our employees to maximize their talents in developing innovative technologies, reliable products, and satisfactory services by placing our priority on the well-being of every staff member at Getein. 

Incorporated in 1994, Tasly Holding Group has now developed to an internationalized and high-tech cooperation, engaging in the pan-health industry with the biological medicine industry as the core business, health industry, and medical service as two supporting businesses.              

Guided by ancient Chinese civilization, Tasly is devoted to the philosophy “seeking for harmonization between human and nature, improving humankind’s life quality” . With the mission of “to share the joy of health with all”, Tasly aims to become the No. 1 in modern biological pharmaceuticals and leader of the integrated health industry in China. By now, Tasly has set up a pan-health industry line, which contains six core industries，including the bio-pharmaceutical industry, health products industry, herbs industry, medical industry, health management industry, and children education industry.

Aiming to realize TCM globalization, Tasly has been sticking to develop the international market since its foundation. By now,  more than 30 types of preparation products in 8 medical categories of Tasly have been put into the global market. And the export routes cover 23 countries in America, Europe, Africa, and Asia. With the distribution network spreading to more than 40 countries, Tasly’s distributor members have almost reached a million in the world. In recent years, Tasly has been listed in the top 10 of TCM exporters in China. And in 2016, Tasly Pharm. Co., Ltd was named the Top 500 of Chinese Enterprises released by the US Fortune magazine.

In September 2002, SHINVA successfully went public at the Shanghai Stock Exchange. It is now the chairman unit of China Association for Medical Devices Industry (CAMDI). We unshakably walk the way of a healthy industry, technical innovation and capital operation, now being the leading medical enterprise in China that is based on medical instruments and equipment, pharmaceutical equipment and preventive medicine service and can provide customers with the main 9 production lines: CSSD integrated solutions, pharmaceutical computer integrated solutions, radiotherapy integrated solutions, digital operating room integrated solutions, integrated dental solutions, medical, environmental protection integrated solutions, experiment animal safeguard integrated solutions, in vitro diagnostic reagents and instruments and biomedical materials and supplies. Among them, the quality and market of the CSSD integrated solutions, pharmaceutical equipment integrated solutions, and radiotherapy integrated solutions both rank the front in China. Every year we have many new products that come into the market.     

Now we have 14 state-level products. We have gained the famous trademark of China and are the first domestic medical enterprise that owns a state-level enterprise technical center. Shandong province is the center of development, manufacturing, marketing, and management, and we have two core areas: Shanghai and Beijing, forming our basic layout. Standing at the new developing stage of history, facing new chances, SHINVA will always advance with the times, act with self-confidence, innovation, and hard work.

KPC Pharmaceuticals, Inc (‘KPC’, 600422 SH) was established in March 1951 and floated on the Shanghai Stock Exchange in December 2000. With its considerable professional experience in the pharmaceutical industry, the company is listed as one of the new key national high-tech companies and one of the Top 100 companies in the Chinese medical industry. The company’s brands, such as Luotai®, Tianxuanqing®, Artemedine®, Artem®, and Arco® , earned the company a good reputation both at home and abroad.

KPC is a pharmaceutical company that focused on innovative natural botanical drugs and integrated R&D, production, marketing, commercial wholesales, and international marketing. Its business scope covers Traditional Chinese Medicine, chemical medicine, and medicinal circulation. Companies owned by KPC include the Kunming Traditional Chinese Medicine Co. Ltd., Kingtide Notoginseng Industry Co. Ltd., Xishuangbanna Pharmaceutical Co. Ltd., Kunming Pharmaceutical Commercial Co. Ltd., Kunming Baker Norton Pharmaceutical Co. Ltd., Nukus Botanic Technology Co. Ltd., Kunming Yinnuo Medical Technology Co. Ltd., and Beijing Holley-Cotec Pharmaceuticals Co. Ltd. KPC also boasts a large-scale manufacturing center, Xuesaitong drug research institute, and postdoctoral workstation. Situated in the National Biological Industry Base of the Kunming High-tech Zone, the “KPC Bio-Pharmaceutical Science and Technology Park” will be a large-scale, professional and international biomedical park, taking the lead both at home and abroad.

Based on Yunnan’s abundant plant resources, KPC has developed more than 40 new natural botanical drugs, including the artemether series, Panax Notoginseng series, Gastrodine series, special Chinese medicines, and special ethnic drugs. With multiple national patents, KPC has filled several gaps in the pharmaceutical industry both at home and abroad. Being highly renowned and popular in terms of treatments for cardio-cerebral-vascular diseases, nervous system diseases, and malaria, KPC has made positive and significant contributions to the health of humans.

KPC’s unique core competitive advantages include its outstanding R&D ability, abundant product resources, robust integrated manufacturing system, internationally compatible quality management system, and its international marketing team. In the future, following the principle “From nature; For Human Health”, KPC will develop into a global pharmaceutical supplier focusing on cardio-cerebral-vascular disease and chronic disease treatment. At the same time, it will continue striving to be a leading and globally famous brand in terms of cardio-cerebral-vascular drugs.

Founded in 1988, WEGO works on developing medical devices and pharmaceuticals as its primary business, while expanding the architectural engineering, finance, and other areas. With more than 80 subsidiaries, 2 listed companies, and more than 30,000 employees, WEGO Holding Co., Ltd., which covers an area of more than 60 million square feet, consists of WEGO Group, WEGO Architecture Engineering Group, and WEGO Financial Holding Group. WEGO has 7 industry groups, including medical products, blood purification, orthopedics, medical equipment, pharmacy, intracardiac consumables, and medical business.

Main products of WEGO are infusion sets, syringes, blood transfusion equipment, intracardiac consumables, IV catheters, and special needles, blood purification equipment and consumables, orthopedic materials, operating equipment and accessories, trauma care, surgical robots, minimally invasive instruments and equipment, ICU products and accessories, high-capacity injections and other pharmaceuticals, renal products, biological diagnostic reagents, surgical sutures, dental implants, sense control equipment and consumables, PVC & non-PVC materials and so on. With more than 1000 varieties of products provided in more than 150,000 specifications, WEGO’s medical instruments now have entered into 11 fields out of 15 segmented markets, becoming one of the safest and reliable suppliers of medical system solutions in the world.

In order to further improve the innovation system, WEGO has established a national-recognized enterprise technology center, a national engineering laboratory of implants, a national innovation pilot enterprise, an academician workstation, a postdoctoral workstation, Shandong High-performance Medical Device Research Center, Shandong Medical Device Technology Innovation Center, a provincial engineering technology research center, Taishan Scholar Laboratory and other innovation platforms, accelerates the construction of three major platforms including WEGO Research Institute, National Innovation Center and Beijing & Changchun R & D Center, and carries out industry-university-research cooperation with more than 30 well-known universities and research institutes such as the Chinese Academy of Sciences, the Chinese Academy of Engineering, the Academy of Military Medical Sciences, Chinese PLA General Hospital, Harbin Industrial University and Tianjin University, with over 30 research institutions established.

WEGO has more than 1,100 patents, including more than 400 invention patents, possesses more than 900 products with independent intellectual property rights, among them, high-tech products and high value-added products account for more than 80%.  WEGO also has products such as orthopedic materials series, blood purification series, intracardiac consumables series, artificial liver, automatic chemiluminescence analyzer, color ultrasonic diagnosis, DR, prefilled syringes, membrane oxygenator, and protein A immunoadsorption column have broken foreign monopolies and become well-known international brands, etc.

Founded in 2004, Double Medical Technology Inc. (Ticker Symbol: SHE:002901) is one of the key high-tech enterprises and a large medical equipment group. With its six subsidies, Double Medical offers service, technology, and device in the area of orthopedics, wound management, neurosurgery, and general surgery. Double Medical′s orthopedic implants are a leader in the domestic market in China. Dedicated to rehabilitation, Double Medical focuses on providing high-quality, affordable products, quick logistics, and constant doctors’ support. The products are CE 0120 certified, approved by FDA 510(K), and Australian TGA.

Double Medical has branches in over 30 provinces and cities and is cooperating with more than 3,500 hospitals and nearly 1,000 business enterprises in China. Its products have been exported to more than 50 countries and regions that include EU, Russia, South  America, Australia, Southeast Asia, Middle East, and South Africa.

Established in 2005, Shanghai Kinetic Co., Ltd. has become a medical device manufacturer for multidisciplinary specialties, including Orthopedics, Cardiovascular, and Sports Medicine.

KMC was listed on the Growth Enterprises Market of Shenzhen Stock Exchange (3000326.SZ) in 2012, merged Beijing Essen and Jiangsu Ideal the second year.

While rapidly growing, KMC is also continually building up a creditworthy company image and creating strategic cooperation platforms at home and abroad by diversifying product lines, enhancing product quality, and completing service systems.

KMC keeps active communication with KOLs for consistent improvement and innovation to the products and medical solutions. It will always stick to the company’s original mission “to provide top quality products and the best value to the needs of the doctors and patients” simultaneously.

Chongqing Pharscin Pharmaceutical Co., Ltd. (“Pharscin Pharma”) is a large pharmaceutical company with the functions of R&D, manufacturing, and sales. The company focuses on both Chinese and Western medicines. On October 20, 2017, Pharscin Pharma launched its initial public offering of A-shares on Shenzhen Stock Exchange.(Stock code 002907). The company has 3 wholly-owned subsidiaries, namely Chongqing Pharscin Medicine Co., Ltd., Chongqing Pharscin Pharmacy Retail Chain Co., Ltd. and Chongqing Pharscin Biotech Co., Ltd.

Guided by the technology-led and innovation-driven principle, Pharscin Pharma stays committed to manufacturing high-quality products with special, sophisticated, unique, and novel features. At present, we have 68 drug varieties, including Chinese patent medicine, APIs, and finished pharmaceutical products. Among them, 49 drugs are in the catalog of National Medical Insurance, 46 drugs have domestic patents, and one has international patents.

Pharscin Pharma attaches great importance to scientific and technological innovation and has built a robust, innovative platform for the transformation of scientific and technical achievements. We have successfully applied the key technologies such as extraction of thermosensitive active ingredients of traditional Chinese Medicine, automatic transmission of powders, and production control of soft capsules into manufacturing. The company is now in the process of building an automated information management system, purposely realizing the informative,internet-based, digital, and intelligent management of production through the automated module control in every link of production.

Pharscin Pharma has built 11 domestically leading production lines for multiple dosage forms, including tablets, powders, granules, hard and soft capsules, powder for injection, freeze-dried powder for injection, small-volume injection, API syntheses, and botanical drug extraction, etc. Our manufactured products have a 100% passing rate in the finished product inspection, sampling inspection of the NMPA(former CFDA), national evaluation sampling inspection, and market sampling inspection.

Pharscin Pharma stays committed to academic promotion and has built a professional marketing team of more than 500 medical representatives to deliver advanced, accurate, and up-to-date information and services to medical workers. Our marketing network covers 31 provinces, cities, and autonomous regions, and is establishing its presence in overseas markets.

Established in 1996, IDEAL continually sticks to the guiding ideology of centering on science & technology, takes market as guiding orientation, takes meeting demands as its own duty, manufactures orthopedic implants and instruments with high-tech, refined equipment, and quality management, which ensure the quality of the implants to achieve the international level and set up a national brand.

IDEAL is a specialized enterprise that integrating developing, manufacturing, and marketing Class III implanting materials and Class II orthopedic surgical instruments. The trademark is registered as “IDEAL”.

In 2014, IDEAL completed a joint venture with Shanghai Kinetic Medical Co., Ltd. After 20 years of sustained development, IDEAL has now become an orthopedic medical device professional manufacturer. The company covers an area of nearly 20,000 square meters. The total area of housing construction is over 20,000 square meters, of which, production, research space over 15,000 square meters. The total assets are over 0.1 billion RMB, of which, manufacturing, research, and development, testing equipment accounted for the total fixed assets of 60%. The company has world-class production machines, such as USA Haas vertical boring and milling processing center, Germany’s DMG boring and milling processing center, South Korea’s Hanhua turning center, and five-axis vertical boring and milling machining center.

The company attached great importance to the cultivation of innovative technology and product and now owes 11 patents. In 2010, it obtained a provincial high-tech enterprise. It established cooperation with Shanghai universities and colleges, for example, medical device R&D center, graduate workstation, postdoctoral innovation practice base, which provide strong talent protection for its development.

Innovative Material and Devices, Inc. (IMD), established in Shanghai, China in 2004, is a Sino-American joint venture company that engaged in R＆D, manufacture, and sales of new functional material applied in Medical fields.

IMD is engaged in the development and manufacturing of new biological materials, which are widely applied in all aspects of Medicine. The company owns a set of advanced and sophisticated production technology and equipment, and also sales our manual and rotary NiTi files, NiTi pluggers and NiTi archwires, Bracket, etc.

Shenyang Sinqi Pharmaceutical Co., Ltd. is a state-level high-tech enterprise professionally engaged in ophthalmic R&D, production, and sales. With the responsibility of revitalizing the Chinese national medical industry, Sinqi is wholeheartedly committed to the specialty of ophthalmology. In 2007, Sinqi Pharmaceutical R&D Center was named after the “Liaoning Sinqi Pharmaceutical Engineering and Technological ResearchCenter” by Liaoning Science and Technology Bureau. In 2014, Sinqi Pharmaceutical smoothly passed the 2010 national GMP certification.

“While forging ahead with determination and daring to struggle”, “Sinqi” has already become a successful ophthalmic brand through its unremitting efforts and innovation made by all Sinqi staff. Sinqi Pharmaceutical is marching towards the leading ophthalmic field with great concentration and persistence, transferring more scientific research achievements into superior products to serve public health and become a competitive brand across the world. At present, the company possesses ten series of more than 30 products such as antibacterial drugs, anti-inflammatory agents, artificial tears, cornea repair drugs, antiviral agents, anti-allergic drugs, antifungal drugs, mydriatic drugs, operation drugs, glaucoma curatives, etc. It has developed 6 original research drugs and 9 patent drugs so as to offer high-quality products to the curative field of ophthalmic diseases.

Founded in July 2009, the Sinqi Philanthropic Foundation was created with contributive capital of RMB 1 million by Newsun, Chairman and General Manager of the company. Along with its predecessor, the Sinqi Sunshine Foundation, the Sinqi Philanthropic Foundation signifies new progress that the company has made towards philanthropic relief action, and symbolizes Sinqi staff’s determination and confidence in shouldering social responsibilities.

Guanhao Biotech is a company focusing on the regenerative medicine industry, expanding its business to life science fields. The company builds bridges to globe-wide high-end technological resources and achievements and keeps investing in the area of biomaterials, stem cells, pharmaceutical industry, and advanced medical technologies, resulting in the form of “3+1” branches, namely the material, the cell therapy, the pharmaceutical branches, and a tech incubator platform.

The company has established a globally competitive medical technology platform of animal-derived biomaterials in the field of regenerative materials after more than a decade’s developing time. Relying on its leading level in the inducible regenerative functional biomaterials, the company has been involved in more than twenty national or local scientific projects and has become the national research center and the industrialization demonstration base in this field. The Regenerative Medical Implanted Machine National Engineering Laboratory and The Regenerative Biological Membrane High Technology Industrialization Demonstration Project have been successively appointed to Guanhao Biotech by The National Development and Innovation Committee. In the present, the company holds hundreds of national or world patents and has marketed original products including NormalGEN dura repair patch, GrandNeuro (Type B) dura repair patch, ThromalGEN (Type P) surgical patch, ThromalGEN (Type B) surgical patch, DermalGEN wound dressing, IREAL breast patch and Youvision Acellular corneal graft. As well as the artificial lens products represented by Zhuhai Xiangle, they can be widely used in neurosurgery, thoracic surgery, ophthalmology, dermatology, orthopaedics, cosmetology and so on.

In the fields of cell and stem cell therapies, the company sets steps in autologous chondrocyte implantation (ACI), immune cell bank in the present, and starts to invest in immune cell therapy R&D. In the stem cell area, the company cooperates with the professor Hongkui Deng’s research team from Beijing University and has established the Bei Hao Stem cell and Regenerative Research Institute, aiming to build up a world-class platform in generality key technologies of immune cells and to gather global talents and technologies for translational stem cell R&D.

Guangdong Zhonghao Pharmaceutical Co., Ltd. and Beijing Wenfeng Tianji Pharmaceutical Technology Co., Ltd., which are controlled by the company, both of which holds the intellectual property of 1.1 class new drug Benvitimode in the China region. Benvitimode is a non-hormonal small molecule chemical isolated from natural microbial metabolites. The Medicine is the world’s first; it can be used in the treatment of certain autoimmune diseases, for example, psoriasis (commonly known as “scaly tetter”) and eczema; and it was listed as “The 12th five-year plan” national “major new drug creation” major science and technology projects by National Ministry of Science and Technology. In May 2019, Benvidimod Cream, a class of innovative drugs, was approved to be marketed through the priority approval procedure of the State Drug Administration. The product is used locally for the treatment of mild to moderate stable psoriasis Vulgaris in adults.

In the science and technology incubation sector, Guanhao Science Park initiates the professional innovation incubation mode of “listed company + Incubator + industry fund”, strives to build the most professional industry-financed interactive life-health innovation and entrepreneurship Incubation Platform in China, and provides the overall solution of entrepreneurship projects and packaging services of industrialization transformation. In December 2017, Guanhao Science Park was identified as a state-level incubator of science and technology enterprises.  

Neusoft Medical Systems Co., Ltd. (Neusoft Medical) is a leading global clinical diagnosis and treatment, solution provider headquartered in China, with subsidiaries in the United States, Dubai, Peru, Russia, Brazil, Kenya, Germany, Korea, Thailand, and a representative office in Vietnam.

Neusoft Medical is continuously innovating its portfolio of medical imaging diagnosis and clinical solutions in CT, MRI, DSA, XR, PET/CT, RT, US, and IVD. Neusoft Medical also is developing MDaaS (Medical Devices & Data as a Service), a strategic product line built using the Internet, big data, artificial intelligence, combined with other technologies improving medical institutions’ ability to diagnose and treat patients, achieving operational excellence.

Innovation is always the driving force of Neusoft Medical. The global R&D centers are located in Houston, Seoul, Beijing, Shanghai, Shenyang, Guangzhou, and Nanjing. Neusoft Medical is collaborating with global scientists and medical institutions dedicated to advancing the technology of medical imaging solutions.

Together with 38,000 installations in more than 100 countries, Neusoft Medical provides advanced, high-quality medical imaging solutions to patients around the world.

Contec Medical Systems Co., Ltd. (hereinafter referred to as CONTEC), focusing on research, manufacture, and distribution of medical instruments, was founded in 1996 as a high-tech company. CONTEC locates in Economic & Technical Development Zone in Qinhuangdao is one of the largest bases for R & D and production of medical devices.

CONTEC was dedicating to research, manufacture, and distribution of medical devices, now we have developed more than 20-category products contained Pulse Oximeter, Sphygmomanometer, ECG, EEG, Ultrasound Equipment, Patient Monitor and Image Equipment, etc. And we have established a modern scientific and practical manufacture system and management system, independently designed and developed many advanced products, such as Pulse Oximeter, Electronic Sphygmomanometer, Blood Pressure Monitor, Arteriosclerosis Examine, 1-12-channel ECG, Portable ECG Monitor, ECG Workstation, Digital Brain Electric Activity Mapping, Dynamic EEG System, Pocket Fetal Doppler, B-ultrasound Diagnostic System, Sleep Apnea Screen Meter, Polysomnography Analysis System, Pulse Rate Meter, Spirometer, Urine Analyzer, Oxygen Concentrator, Patient Monitor and Multi-parameter Vital Signs Monitor. We own more than 100 national patents, 56 software copyright, our products have passed CE, FDA, and COS/VIOS certificate. At present, CONTEC products were distributed to over 130 countries and regions. 

CONTEC adheres to the people-oriented, innovative development ideas, endeavors to achieve the goal of the international market, informative management, diversifiable product, we also dedicate to research and product high-tech products with more advanced in technology, more perfect in function, and more predominant in performance, to work CONTEC to a world-class modern enterprise.

Mednova ( Mednova Medical Technologies Co., Ltd. ) located in the high-tech zone of Hangzhou, the most beautiful city of China, is a developer and a provider of modern digital medical imaging systems and solutions.
Mednova’s great expertise and innovation capabilities in medical imaging technologies and systems lead to the birth of a whole new generation of digital x-rays machines：Staray DR systems. Staray offers the highest cost-to-performance ratio that clients appreciate, for its great image quality, its ease of use, its durability, as well as its low cost. Staray is designed to satisfy the needs of the medical imaging markets worldwide: digital, high performance, and low cost. 
In fact, Mednova’s Staray DR systems are just the first step towards the realization of a brand new and highly effective modern digital imaging platform. Mednova’s Micro Dose Digital Mammography and Digital panoramic machine, as well as Digital Vet DR have been launched from 2012 to 2014. A wave of new low-cost digital medical imaging systems based on that platform will also be rolled out in the coming years. They will play an increasingly important, sometimes even decisive role for replacing all less effective analog imaging equipment with fully digital systems.
Since most essential components are developed in-house, Mednova is capable of providing a wide range of customized systems and solutions based on the specific needs of our customers at a low cost. To distributors end-users worldwide, Mednova can provide fully customized high performance and low-cost systems to meet your needs and budget. To current DR makers, Mednova can provide critical components, such as CCD DR detector and the software, to significantly lower your DR system cost. For companies with limited development capabilities, high manufacturing cost, Mednova provide turn-key OEM and ODM solutions, which will dramatically shorten the product development cycle and substantially lower the product manufacturing costs.  It helps companies to focus on marketing and sales of medical systems, save lots of R&D costs, and virtually eliminate the high risks of possible development failures. Mednova would like to invite anyone interested in digital medical image systems and solutions to participate in this win-win business partnership. 

Established in 1999, Micro-Tech strives to improve people’s health. With our high-quality offerings, we want to support physicians and nurses in their daily work and are always seeking new and innovative solutions for the requirements of today’s hospitals, clinics, and physician practices.

By 2003, Micro-Tech has built a widespread reputation in the field of non-vascular stents in China. In 2003, Micro-Tech started to develop disposable accessories of the endoscope from disposable biopsy forceps. Over ten years, Micro-Tech has been devoting itself to proprietary IP, technologies & special “know-how”, advanced facilities, rigorous quality control system. Rooted in the “World Plant”, China, we have more opportunities to improve cost control of manufacturing processes.

Now, Micro-Tech runs its own R&D, engineering, production, and logistic departments – from the original idea to the delivery of the final product everything is in house. In addition, Micro-Tech is taking joint-research with medical institutes and university laboratories. The joint project of “R&D and Application of New-type GI Stent” with Southeast University was approved as Award Grade Two of National Science and Technology Progress in 2011.

Micro-Tech has built a dedicated team to respond to this fiercely competitive and rapidly changing market. In 2007, Micro-Tech Europe was established in Germany as the direct sales and services channel to the European market.

Micro-Tech has become the largest manufacturer of non-vascular stents and disposable biopsy forceps in China. The main products, including stents, disposable biopsy forceps, dilatation balloons, and others, have covered above 50% market share in China. Outside China, Micro-Tech sells products to Europe, North America, and Oceania, etc.  Micro-Tech also provides OEM/ODM service to well-known international companies in the medical device field.
Micro-Tech has been working for developing innovative instruments in the field of minimally invasive surgery for ten years. We are adept in working together with clinicians, sales partners and suppliers. So Micro-Tech has a dream of being the best “innovative plant” trusted by clinicians and partners.

Mindray, founded in 1991, is a leading global developer, manufacturer, and supplier of medical devices whose mission is to deliver high-quality, richly featured medical products making healthcare more accessible and affordable around the world. Mindray provides solutions in three core businesses: Patient Monitoring and Life Support, Medical Imaging, and In-Vitro Diagnostics.

With corporate headquarters located in Shenzhen, China, and 42 international subsidiaries with branch offices in 32 countries, Mindray has approximately 7,500 employees worldwide.  Eight global R&D centers and an industry-leading investment of 10% of annual revenue into research and development further demonstrates Mindray’s commitment to innovation and advancing technology in a global market.

In 2008 Mindray acquired Datascope’s patient monitoring business, which offered a wide range of patient monitors in the OR, emergency care, and critical care environments for over 50 years.  With that acquisition, Mindray has become the third-largest player in the North American and global patient monitoring markets, and the third-largest supplier of anesthesia systems as well.

Another milestone was the 2013 acquisition of ultrasound technology leader Zonare Medical Systems, based in Silicon Valley, California, solely dedicated to ultrasound excellence through its next-generation, software-based ZONE Sonography® Technology (ZST). This innovative technology provides the platform for the company’s Living Technology – a continually evolving architecture to meet the changing imaging needs of the clinician.

Today, Mindray products and services can be found in healthcare facilities in over 190 countries and regions.

Founded in 1994，Make endoscopic diagnosis and treatment more accessible and convenient.

After more than 20 years of dedication and innovation, Aohua’s products have covered multiple clinical departments such as gastroenterology department, pneumology department, otolaryngology department, emergency department, anesthesiology department, and ICU.

Aohua envisions itself to become the world’s leading provider of overall endoscopic solutions. It’s mission is to make endoscopic diagnosis and treatment more accessible and convenient.  Aohua Values: Dedication, innovation, continuous learning, customer satisfaction, and win-win.

Jumpcan Pharmaceutical is a national high-tech enterprise group, the National Torch Program pharmaceutical industry backbone enterprise, one of top 100 of the national pharmaceutical industry, and the Shanghai Stock Exchange A-share listed company (stock code: 600566), and focusing on the R & D, manufacturing and trading of Chinese Traditional Medicine, Western Medicine, daily use chemical-based on Chinese Traditional Medicine, and Chinese medicine health products. The company has two subsidiaries, Jumpcan Pharmaceutical Group Co., Ltd. and Shanghai Jijia Investment Co., Ltd. Jumpcan Pharmaceutical Group Co., Ltd. has several subsidiaries including Tianji Pharmaceutical, Jiyuan Medicine, Jiren Medicinal Slices, Pudilan Daily Use Chemicals, Kangxuyuan Health Products, Ginkgo Industry Research Institute, Oral Health Research Institute, and Haiyuan Property; Shanghai Jijia Investment Co., Ltd. has few subsidiaries including Ningbo Jijia Investment and Dongke Pharmacy.

The company has more than 10 formulations, over 210 strengths and specifications of No. National Drug of Character Zhun, where more than 110 advantages and specifications are included in the National Directory of Insured Drugs, 68 strengths and specifications are included in the National Directory of Basic Drugs.

The company obtained 38 national invention patents, with more than 10 varieties listed as the Exclusive Domestic Varieties, Exclusive Formulations, High-tech Products in Jiangsu Province. It’s brand including Pudilan, Methylene Blue, and Chuanxiong, “Shoupai” and “Tongxiao”. It’s Pudilan Anti-inflammatory Oral Liquid obtained “The Fourteenth Excellent National Patent Award” and “Excellent Quality Award”.  The new generation of proton pump inhibitor Rabeprazole Sodium Enteric Capsules (Jinuo) won the title of “2015 Excellent Brand of Digestive System in Chinese Chemical Pharmaceutical Industry”.  one pharmaceutical composition for curing exogenous fever and its preparation method (Tongbei) also won the 17th Excellent Chinese Patent Award. The daily use chemical-based on Chinese Traditional Medicine led by “PudilanKeyanning Toothpaste” and Chinese medicine health products led by “Wuxiancao” will keep enhancing the company’s core market competitiveness and promoting the rapid development of big health undertaking.

Established in 1995, Guizhou Sanli Pharmaceutical Co., Ltd. is a modern Chinese patent medicine pharmaceutical enterprise integrating R&D, production, and sales. The company’s product line mainly focuses on pediatrics, respiratory system, cardio-cerebrovascular, gastroenterology, and other fields.

The main products are Kaihoujian spray (child type), Kaihoujian spray, and Qiangli Tianma Eucommia capsules. Among them, the core products Kaihoujian spray (children’s type) and Kaihoujian spray are all national patent products and exclusive varieties in the market. The patent medicine spray market in the throat disease occupies a higher market share and has been used in throat diseases, children A certain brand awareness has been formed in the field of Chinese patent medicine. According to the statistics of the Southern Institute, Kaihoujian spray (including children’s type) ranks first in the throat disease patent medicine spray market, ranking first for three consecutive years, and the throat disease patent medicine spray hospital terminal market has been consecutively Ranked No. 1 in the annual market.

Shanghai Shuangshen Medical Instrument Co,. Ltd. was founded in 2005, headquartered in Shanghai, Qingpu District, Zhangjiang Technology and Industry Park. With its 1.4ha. corporate premises and 120,000 s.f. factories and office building, Shuangshen is a state-chartered medical products manufacturer in the People’s Republic of China.
We produce high-quality CRANIAL MAXILLOFACIAL INTERNAL FIXATION SYSTEMS. Our products are tested and certified by the state institution, have already found application in 500 Chinese hospitals, and have won considerable confidence from physicians and the satisfaction of patients.
Our team consists of 50 qualified and dedicated staff. We apply the highest standards to the quality assurance of our products and the reliability of our services. Our products are researched and developed in collaboration with leading clinics, research institutes, and universities.
In 2014 the company was transformed into a stock corporation, and its shares are traded on the Shanghai Stock Exchange. With an optimistic look to the future, we attach great importance to the continuous development of our products. Our researchers and developers are working on new solutions for neurosurgery, thoracic surgery, and dental implant systems to improve and expand our competencies. Our goal is: in the near future to expand Shuangshen with the help of innovative technology to a leading Chinese market entrepreneur at world quality level.

Yabao Pharmaceutical Group Co., Ltd. is the first listed pharmaceutical company in Shanxi Province and one of the first batch of recognized high-tech enterprises. Integrating R&D, production, logistics, distribution, and planting of traditional Chinese medicines, Yabao has 21 branches and subsidiaries, and over 5600 employees in total. 

Among over 5030 domestic pharmaceutical enterprises, Yabao is ranks 87th.  The Ministry of Industry accredits it as China’s top 100  pharmaceutical enterprises.  Its innovation power is in the top 20, regarded as China’ s best industrial enterprise for the pharmaceutical R&D product line. The trademark of “Yabao” has become a renowned China brand.  

Yabao has 9 production bases in Beijing, Shanghai, Taiyuan, Chengdu, Guiyang, Yuncheng, America and etc, 4R&D bases, 2 traditional Chinese medicine planting bases. All the 9 production bases have passed the new GMP certification, with Beijing Yabao Biopharma having passed the cGMP certification and the No. 3 Branch passed EU GMP certification.

The main products include Chinese and western medicines, APIs and pharmaceutical packaging materials, and the like of over 300 varieties in total. The products for chronic diseases in the elderly and for women and children take a very high share. The patent product, Diarrago, is a national famous-brand. It was awarded the first-class prize of science and technology by the China Association of Chinese Medicine in 2006. and ranked first in Chinese over-the-counter products in 2015. It is the first brand of drugs for children’s external use in China, with a market share of more than 90%.

The company has a globalized professional R&D team, which is composed of 460 R&D staff in total, including 22 Dr. and 150 Masters. Yabao has taken steps to international practice in new drug application, production, and distribution, following the international strategy of  ” research in China and declaration in China, USA, and Europe; production in China and distribution in China, USA, and Europe”.

With more than 3000 salesmen, Yabao has established professional marketing and sales teams  for business channels, OTC retail, terminal at the grass-roots level, hospital investment, OTC investment, APIs, sales development, Beijing biological Pharma, health care consumer products and etc. The company has a perfect sales network, which covers the first, secondary and third markets and terminal markets in 661 counties of 32 provinces and cities. 

China National Pharmaceutical Group Co., Ltd. (Sinopharm) is a large healthcare group directly under the State-owned Assets Supervision and Administration Commission (SASAC) of the State Council, with 128,000 employees and a full chain in the industry covering R&D, manufacturing, logistics and distribution, retail chains, healthcare, engineering services, exhibitions and conferences, international business and financial services.
Sinopharm owns over 1,100 subsidiaries and 6 listed companies which are Sinopharm Group Co., Ltd. (Sinopharm Holding), China National Medicines Corporation Ltd., China National Accord Medicines Corporation Ltd., Beijing Tiantan Biological Products Co., Ltd., Shanghai Shyndec Pharmaceutical Co., Ltd., and China Traditional Chinese Medicine Holdings Co., Ltd.
The past years witnessed Sinopharm’s steady and sound development. From 2009to 2018, the CAGR of revenue and total assets reached 24.24% and 30.54%, respectively. Sinopharm ranked 169th in Fortune Global 500, and the revenue of 2018 amounted to nearly 400 billion RMB.
Sinopharm has built a nationwide logistic and distributing network for drugs and medical devices and equipment, including 5logistic hubs, more than 40 provincial-level centers, and over 240 municipal-level logistic sites. By establishing the smart medical service system, Sinopharmdelivers quality services of more than 230,000 corporate clients.
Sinopharm has an applied pharmaceutical research institute and an engineering design institute, both taking a leading position in China. Two Academicians of the Chinese Academy of Engineering, 11 national R&D institutes, 44 provincial-level technology centers, and over 5,000 scientists have made remarkable achievements. Sinopharm also chaired in setting over 530 national technical criteria, among which the EV71 vaccine, the first category new drug of China with Sinopharm holding complete independent intellectual property rights, reduces the morbidity of hand-foot-and-mouth disease among Chinese children. The R&D and launch of sIPV ensure the progress of the national immunization program for polio.
Sinopharm has built up manufacturing and medicinal materials sites for biological drugs, narcotic and psychotropic drugs, anti-infectious drugs, oncology drugs, cardio-vascular drugs and respiratory drugs. Some of the production lines have been approved by the US FDA and EU authorities, and prequalified by WHO.
As world’s 6th largest vaccine manufacturer, Sinopharm is able to produce all the vaccines in the National Vaccination Program and is the supplier of over 80% vaccines used in the Expanded Program on Immunization in China.
Sinopharm leads in TCM sector by establishing an integrated TCM industry chain that covers planting, R&D, pieces for decoction, formulated instant granules, and preparations. It is able to produce over 900 medicines,owns 15 China Time-honored Brands and 4 National Intangible Cultural Heritage medicines.
Sinopharmhas fostered 30 highly recognized events represented by CMEF (China International Medical Equipment Fair), serving the entire chain and many subdivisions concerning healthcare. These exhibitions and conferences have become a platform for exchange and cooperation that advances the whole industry.
Sinopharm explored a new model of drugstores with extensive healthcare services. There are over 5,100 chain drugstores under the brands of Guoda, Jinxiang, Dadesheng, and Tianyitang, providing convenient access for customers. Sinopharm forms a healthcare network consisting of regional healthcare groups in provinces of Henan, Hubei, Liaoning, and Heilongjiang. Sinopharm provides easier access to healthcare services for the people in dozens of our medical institutions, with more than 10,000 beds in total.
Sinopharm broadens its international cooperation by founding 26 joint ventures with world-renowned pharmaceutical companies and trading with more than 120 countries and regions, including60 Belt and Road countries.
The JE vaccine, of which Sinopharm owns complete independent intellectual property rights, has been listed in the procurement catalog by the UN organizations to benefit the whole world. Sinopharm’s production sites in Vietnam and Malaysia, along with the China-aided hospitals and mobile clinics constructed by Sinopharm in Myanmar and Cambodia, provide not only jobs for the local people but also make significant contributions to their well-beings.
As healthcare-centered financial services develop, an industry-and-finance model with Sinopharm features takes shape.
Sinopharm acts as the president enterprise in many influential associations such as China Pharmaceutical Industry Association, China National Narcotic Drugs Association, China Association of Pharmaceutical Commerce, etc., and plays its role in preventing diseases, safeguarding people’s health, and advancing the whole industry.

In 2001, Hainan Sihuan Pharmaceutical Co., Ltd. was founded, marking the starting point of the entrepreneurial development of Sihuan Pharmaceutical Holdings Group. At its start stage, Sihuan Pharmaceutical attached great importance to marketing. Later, with the establishment of Hainan Sihuan Cardio-Cerebral Vascular Drug Research Institute, it is able to make progress both in market development and new product R&D, thus facilitating the company to develop rapidly. Later, through capital operation such as merger and acquisition, it further improved its industrial chain by successively incorporating Beijing Sihuan Pharmaceutical, Shenzhen Sihuan Pharmaceutical, and other companies into Sihuan Pharmaceutical, developing into a pharmaceutical group with integrated R&D, production and sales capabilities.
Sihuan Pharmaceutical Holdings Group was incorporated in Bermuda in April 2006 and was successfully listed in Singapore in March 2007. In 2009, in order to meet the needs of greater development, Sihuan Pharmaceutical Holdings Group completed privatization and was delisted from Singapore, and was successfully re-listed in Hong Kong in 2010.
Up to now, Sihuan Pharmaceutical Holdings Group has developed into a pharmaceutical enterprise with strong R&D capabilities, high-quality product structure, and a sound production management system. Together with a unique marketing model and professional services, it deeply engages in the cardio-cerebral vascular drug industry in China to serve human health, winning wide acclaim from the community and users, and has established a unique brand image of “Sihuan”.

Founded in 1994, Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (“Fosun Pharma”; stock code: 600196.SH, 02196.HK) is a leading healthcare group in China. Fosun Pharma has built a strong root in China and developed a global operation strategy, with pharmaceutical manufacturing and R&D being the largest and core business segment, together with a strong presence in medical devices and diagnostics, healthcare services, pharmaceutical distribution, and retail.
With R&D innovation as a core driving factor, Fosun Pharma continues to optimize its pharmaceutical operations across both innovative and generic drugs. The company has established international R&D centers for excellence in areas such as innovative small molecule drugs, high-value generic drugs, biologics, and cell therapy.
Under the guidance of our 4IN strategy (Innovation, Internationalization, Integration, and Intelligentization), Fosun Pharma follows the brand concept of Innovation for Good Health and strives to be a leading enterprise in the global pharmaceutical and healthcare markets.

Haohai Biological Technology (06826.HK) is a leading company in China, focusing on R&D, manufacturing, and sales of biomedical materials. We strategically target the fast-growing therapeutic areas in the biomedical materials market, including ophthalmology, medical aesthetics and wound healing, orthopedics, and anti-adhesion and hemostasis. We currently manufacture intraocular lenses (IOL), medical sodium hyaluronate, medical chitosan, medical collage sponge, rhEGF, etc. Based on the sales volume of the Company’s IOL and the number of national cataract surgery cases, the company has captured about 30% of the IOL market in the PRC. Meanwhile, the market share of the company’s anti-adhesion products, OVD products, and orthopedics viscosupplementation products was 49.05%, 45.93%, and 36.21%, respectively. 
We believe our R&D capabilities will be the driving force behind our long-term competitiveness, as well as our future growth and development. The company’s in-house R&D team comprised of more than 200 staff members. In 2017, The Company was included in the list of National Enterprise Technology Centers. Also, the company owns one national postdoctoral R&D workstation and one Shanghai municipal academician expert workstation. Haohai Biological Technology had been granted more than 40 invention patents. Moreover, our proprietary medical chitosan and rhEGF was awarded the Second Prize of National Science and Technology Progress” by the State Council. 

Guangzhou Pharmaceutical Holdings Limited (GPHL) is a wholly state-owned enterprise authorized by Guangzhou municipal government to operate state-owned assets. GPHL is dedicated to the research and development of Chinese patent medicine, Chinese Herbal Medicine, chemical-pharmaceutical raw materials and preparations, biological Medicine and healthcare products, and pharmaceutical logistics and distribution and healthcare service.

As a large enterprise winning the municipal government’s key support for development, GPHL integrates the research, manufacturing, and trading of medicine. It consists of one public company, namely Guangzhou Baiyunshan Pharmaceutical Holdings Co., Ltd., which is listed both at the Stock Exchange of Hong Kong Limited (H-Shares) and the Shanghai Stock Exchange (A-Shares), and around 30 subsidiaries.

With a history of 419 years, GPHL has ranked first on the list of China’s top 100 Pharmaceutical Companies for seven consecutive years since 2012 and ranked 165th on the list of China’s Top 500 Enterprises in 2018. The group achieved a sales revenue of over 100 billion yuan in 2017 and 116 billion yuan in 2018, making it the second state-owned enterprise in Guangzhou to record such an achievement.

Established in 1600, Chenliji Pharmaceutical Factory is known as the “World’s Oldest Operating Pharmaceutical Factory” affiliated to GPHL and has been widely recognized as a leading China’s Time-honored Brand pharmaceutical enterprise in southern China.

Neusoft Medical Systems Co., Ltd. (Neusoft Medical) is a leading global clinical diagnosis and treatment, solution provider headquartered in China, with subsidiaries in the United States, Dubai, Peru, Russia, Brazil, Kenya, Germany, Korea, Thailand, and a representative office in Vietnam.

Neusoft Medical is continuously innovating its portfolio of medical imaging diagnosis and clinical solutions in CT, MRI, DSA, XR, PET/CT, RT, US, and IVD. Neusoft Medical also is developing MDaaS (Medical Devices & Data as a Service), a strategic product line built using the Internet, big data, artificial intelligence, combined with other technologies improving medical institutions’ ability to diagnose and treat patients, achieving operational excellence.

Innovation is always the driving force of Neusoft Medical. The global R&D centers are located in Houston, Seoul, Beijing, Shanghai, Shenyang, Guangzhou, and Nanjing. Neusoft Medical is collaborating with global scientists and medical institutions dedicated to advancing the technology of medical imaging solutions.

Together with 38,000 installations in more than 100 countries, Neusoft Medical provides advanced, high-quality medical imaging solutions to patients around the world.